Top

Clinical Research in Cardiology

Published in:

Open Access 01-10-2014 | Letter to the Editors

Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome

Authors: Vincenzo De Santis, Giacomo Frati, Ernesto Greco, Luigi Tritapepe

Published in: Clinical Research in Cardiology | Issue 10/2014

Excerpt

Sirs: …

Dreiher J, Almog Y, Sprung CL, SEPSIS-ISR Group et al (2012) Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: a multicenter analysis. Crit Care Med 40:855–860PubMedCrossRef

Sander O, Welters ID, Foëx P, Sear JW (2005) Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 33:81–88PubMedCrossRef

De Santis V, Vitale D, Santoro A et al (2013) Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol 102:171–178PubMedCrossRef

Lonn EM, Rambihar S, Gao P et al (2014) Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 103:149–159PubMedCrossRef

Hoke RS, Müller-Werdan U, Lautenschläger C, Werdan K, Ebelt H (2012) Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol 101:139–147PubMedCrossRef

Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816PubMedCrossRef

Swedberg K, Komajda M, Böhm M, SHIFT Investigators et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef

Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L (2010) Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol 99:853–855PubMedCrossRef

Nuding S, Ebelt H, Hoke RS et al (2011) Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial. Clin Res Cardiol 100:915–923PubMedCrossRef

10.

Rudiger A, Singer M (2007) Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35:1599–1608PubMedCrossRef

11.

Zorn Pauly K, Pelzmann B, Lang P et al (2007) Endotoxin impairs the human pacemaker current if. Shock 28:655–661PubMed

12.

Steg P, Lopez-de-Sà E, Schiele F et al (2013) VIVIFY (eValuation of the IntraVenous If inhibitor ivabradine after ST segment elevation mYocardial infarction) investigators. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care 2:270–279PubMedCentralPubMedCrossRef

13.

Ackland GL, Yao ST, Rudiger A et al (2010) Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med 38:388–394PubMedCrossRef

14.

Fox KM, Ferrari R (2011) Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 8:369–379PubMedCrossRef

15.

Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691PubMedCrossRef

16.

Jiang J, Tian L, Huang Y, Li Y, Xu L (2013) Pharmacokinetic and safety profile of ivabradine in healthy chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clin Ther 35:1933–1945PubMedCrossRef

17.

Mythen MG (2005) Postoperative gastrointestinal tract dysfunction. Anesth Analg 100:196–204PubMedCrossRef

Title: Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome
Authors: Vincenzo De Santis
Giacomo Frati
Ernesto Greco
Luigi Tritapepe
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 10/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-014-0722-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2014

Post cardiac injury syndrome after initially uncomplicated CRT-D implantation: a case report and a systematic review

Feasibility of sheathless transfemoral aortic valve implantation in patients with small access vessel diameters

Uncommon cause of ST-segment elevation in V1–V3: incremental value of cardiac magnetic resonance imaging

Symptomatic arrhythmias due to syringomyelia-induced severe autonomic dysfunction

The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy

Reply to the correspondence on “Possible spontaneous PFO closure after thrombus trapped in PFO”, Antonia Schulz et al., Clin Res Cardiol 2014; 103:333–335

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page